Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Robert Tatum

Obstetrics Knoxville, TN Medical Doctor

NPI 1699798884 CMS profile 31227

10810 Parkside Dr Ste 100, Knoxville, TN 37934

Open in the dashboard

General payments

$1,729

101 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Robert Tatum of Knoxville, TN is reported in the CMS Open Payments database as having received $1,729 across 101 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 70th percentile of Obstetrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $143 8
2022 General $500 29
2021 General $542 29
2020 General $233 16
2019 General $310 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Tatum
  • Obstetrics median
  • Middle half of Obstetrics
  • National median

In program year 2025, general payments to Robert Tatum were reported at $0. Among 649 Obstetrics profiles paid that year, the median was $181 and the middle half received between $61 and $424.

Show as a table
Year Robert Tatum Obstetrics median Middle half National median
2019 $310 $177 $60–$381 $163
2020 $233 $92 $35–$201 $114
2021 $542 $125 $40–$351 $132
2022 $500 $186 $65–$448 $149
2023 $143 $183 $61–$451 $160
2024 $0 $176 $62–$406 $164
2025 $0 $181 $61–$424 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. AbbVie, Inc. $721 40 payments
  2. Hologic, LLC $138 13 payments
  3. Exeltis, USA Inc. $107 7 payments
  4. Avion Pharmaceuticals $101 5 payments
  5. Daiichi Sankyo Inc. $95 6 payments
  6. Mayne Pharma Inc. $80 5 payments
  7. Vermillion, Inc. $72 1 payment
  8. TherapeuticsMD, Inc. $65 5 payments
  9. Lundbeck LLC $50 3 payments
  10. ASCEND Therapeutics US, LLC $40 2 payments
  11. Other $257 14 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $1,729 101 payments
Products named General payments · program years 2019–2023
  1. LO LOESTRIN FE $338 21 payments
  2. ORIAHNN $207 10 payments
  3. Orilissa Endocrinology $132 6 payments
  4. SLYND $107 7 payments
  5. OVA1 $72 1 payment
  6. INJECTAFER $67 4 payments
  7. Balcoltra $66 3 payments
  8. ORILISSA Womens Health $59 4 payments
  9. Aptima Combo 2 $53 5 payments
  10. VYEPTI $50 3 payments
  11. Other $610 41 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

23

Median for Obstetrics & Gynecology: 65

Drug cost

$347

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

0%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Estradiol Generic 23 $347

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Records

101 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Obstetrics in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record